An Interrupted Vinylogous Iso-Nazarov Reaction: Cycloisomerization of Conjugated Trienones to Cyclopenta[b]furan Derivatives

Martín J. Riveira and Mirta P. Mischne*

Instituto de Química Rosario-CONICET, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, 2000 Rosario, Santa Fe, Argentina

Supporting Information

ABSTRACT: Iron(III) chloride-catalyzed cyclopentannulation of π -conjugated 1,3-dicarbonyl compounds is described. An interrupted vinylogous iso-Nazarov reaction of trienones was established in which cyclopenta[b]furan derivatives are obtained as single diastereomers.



INTRODUCTION

Cycloisomerization reactions are powerful synthetic tools for the construction of polycyclic compounds. Polyunsaturated molecules have been privileged substrates in a vast number of transition-metal-catalyzed and/or electrophile-promoted cycloisomerizations affording five-membered-ring systems.¹ As far as conjugated precursors are concerned, the acid-catalyzed ring closure of cross-conjugated ketones, the Nazarov reaction, has particularly witnessed an outstanding evolution since its discovery, gaining substantial acceptance as an efficient strategy for pentannulation.² To the best of our knowledge, however, only few examples of acid-promoted isomerizations of linearly conjugated π -extended carbonyl systems have been reported (Scheme 1A,B).³ These are related to the iso-Nazarov reaction





of lower vinylogues (Scheme 1C), in which a cyclopentenone is formed via initial conrotatory 4π -electrocyclization of 1-oxypentadienyl cation intermediates.⁴

Our studies of the preparation of extended π -conjugated carbonyl systems via Knoevenagel condensation of 1,3-dicarbonyl substrates (1) and $\alpha,\beta,\gamma,\delta$ -unsaturated aldehydes (2) revealed

that, depending on the substitution pattern and/or electronic properties, products of type 3 can be obtained via cycloisomerization of a primary, nonisolable, coupled intermediate (Scheme 2, path a).⁵ In this manner, a novel stereoselective

Scheme 2. Developed Domino Reaction (EDDA = Ethylenediammonium Diacetate)



annulation cascade for the synthesis of the cyclopenta[b]furan motif, which is present in many biologically active molecules,⁶ was established.

On the basis of our previous research, in which a novel interrelation between cationic species and stability/reactivity of polyene systems has been disclosed, an intriguing question arose as to whether electrophilic activation of isolable polyunsaturated 1,3-dicarbonyl substrates of type 4 could trigger the pentadienyl-cyclopentenyl cation rearrangement/intramolecular cation trapping sequence as a viable cycloisomerization pathway for the assembly of cyclopenta[b]furans (Scheme 2, path b).

In this paper we report the successful realization of such an approach, resulting in a new heterocycloisomerization for the stereoselective synthesis of cyclopenta[b]furans from simple

Received: June 30, 2014 **Published:** July 30, 2014

polyene substrates. From a fundamental chemistry viewpoint, the reactivity displayed by linearly conjugated carbonyl compounds is closely related to Nazarov-based reactions of cross-conjugated ones, expanding the chemistry of cationic 4π -electrocyclizations for the synthesis of five-membered-ring systems.

RESULTS AND DISCUSSION

Taking into account the fact that their specific polarization properties are greatly modulated by not only electronic but also steric factors, we selected unsubstituted polyene **4a** as a model substrate for our initial studies. The effect of Brønsted acids was first examined, and the results are collected in Table 1. While in

Table 1. Screening of Effective Reaction Conditions^a

acid catalyst solvent 0.1M. Me Me reflux н ò 4a ò 5a conv.^b yield entry catalyst (equiv) solvent t [h] CSA (0.5) CH₂Cl₂ 8 95% 30% 1 2 TFA (0.5) CH₂Cl₂ 4 100% 56% 3 BF₃·OEt₂ (2) CH₂Cl₂ 2 100% 80% 4 $PtCl_{2}$ (0.5) CH_2Cl_2 6 30% 6% CuCl₂ (0.5) 5 CH₂Cl₂ >6 30% traces 6 $ZnCl_{2}(0.5)$ CH₂Cl₂ 4 100% 83% 7 $Ti(O^{i}Pr)_{4}$ (0.5) CH₂Cl₂ 6 2.0% traces 8 AuCl₃ (0.5) CH₂Cl₂ 3 100% 65% $AlCl_3$ (0.5) 9 CH₂Cl₂ 1 91% 67% 10 FeCl₃ (0.5) CH₂Cl₂ 4 100% 88% 11 FeCl₃ (3) CH2Cl2 0.25 100% 85% 12 FeCl₃ (0.25) CH₂Cl₂ 82% 50% 6 13 FeCl₃ (0.25) CH2Cl2 6 72% 39% 14 FeCl₃ (0.05) CH₂Cl₂ >50 77% 36% FeCl₃ (0.5) THF 100% 60% 15 1 16 FeCl₃ (0.5) toluene 1 100% 73% 17 FeCl₃.6H₂O (0.5) CH₂Cl₂ 6 95% 70%

^{*a*}Optimization reactions were carried out with substrate 4a (0.5 mmol). ^{*b*}Conversion based on isolated starting material recovered. ^{*c*}Reaction was run at room temperature. ^{*d*}Only distilled, nondried CH₂Cl₂ was used. Abbreviations: CSA, camphorsulfonic acid; TFA, trifluoroacetic acid; THF, tetrahydrofuran.

the presence of mineral acids at room temperature compound 4a rapidly decomposed to give a complex mixture of unidentified products (not shown), organic acids such as CSA and TFA fortunately were able to promote the desired rearrangement toward derivative 5a, which was obtained as a single diastereomer, albeit in low yield (entries 1 and 2). To optimize suitable conditions for this reaction, several metallic and nonmetallic Lewis acids were screened. In this regard, BF₃·OEt₂, ZnCl₂, AuCl₃, and AlCl₃ exhibited promising activities, furnishing the desired product 5a in yields ranging from 65 to 80%, whereas PtCl₂, CuCl₂, and Ti(OⁱPr)₄ proved to be ineffective in promoting the reaction, displaying low conversions of the starting materials and low yields of the isolated products (entries 3, 6, 8, and 9 vs 4, 5, and 7). We were eventually pleased to find that the best results were achieved by using inexpensive and environmentally friendly ferric chloride (entry 10). In regard to catalyst loading, in the presence of superstoichiometric amounts (3 equiv of $FeCl_3$) a rapid rearrangement

of 4a occurs at room temperature, leading selectively to compound 5a in comparable yield to that using 0.5 equiv (entry 11). On the other hand, when the amount of promoter was further decreased, longer reaction times were observed along with deteriorated yields and conversions (entries 12 and 14). The use of other solvents such as toluene or THF provided faster transformations, although a concomitant drop in yield was also observed (entries 15 and 16). The presence of water was shown not to have a significant impact on the reaction, as the use of nondried distilled CH_2Cl_2 or hydrated catalyst (FeCl₃·6H₂O) still allowed for the formation of **5a** in comparable yield to that obtained under anhydrous conditions (entries 12 vs 13 and 10 vs 17).

Having demonstrated the feasibility of introducing the key intramolecular cyclization for the assembly of cyclopenta [b]furan derivatives, we next investigated the effects of polyene structural variations to delineate the scope and utility of the process (Table 2). Six-membered 1,3-dicarbonyl derivatives proved to be good substrates, affording the tricyclic scaffold in yields ranging from 75 to 85% (5b-h). Aryl or alkyl substitution was tolerated both at the end of the triene chain and on the cyclohexanedione ring. Acyclic β -diketones as well as β -keto esters participated in the reaction, although lower yields were obtained in these cases (5i-k). For the preparation of ester 5k, the same yield was obtained starting from either the 2-Z or 2-E isomer of the corresponding polyunsaturated diastereomeric precursor. Remarkably, a different reactivity profile was found for branched trienediones 4l-n, which were stable in the solid state but were found to gradually convert to corresponding cyclopenta [b] furan derivatives 5l-n in deuterated chloroform solution. On the other hand, some substrates did not afford any of the desired cyclopenta[b]furan derivative. Five-membered dicarbonyl olefinic compounds, such as 40 and 4p, remained unaltered under several sets of experimental reaction conditions, as did substrates 4q and 4r in which one of triene double bonds is involved in an aromatic system. On the other hand, trienediones 4s and 4t, both bearing two substituents at the end of the polyene chain, underwent thorough decomposition under FeCl₂ treatment, resulting in complex mixtures.

A consistent stepwise mechanism for the synthesis of products 5 is depicted in Scheme 3. Lewis or Brønsted acid activation of conjugated substrate 4 generates bisallyl cation A, which after a conformational change to the "U form" undergoes a 4π -electrocyclization reaction in a conrotatory manner to give the new cyclopentenyl cation B. Intermediate B may be intramolecularly stabilized by a through-space interaction involving the assistance of the π bond of the enol moiety,⁷ leading to a heavily localized allyl cation that would then be trapped by enolic oxygen to provide *cis*-fused cyclopenta[*b*]furan derivative 5 exclusively. In the case of ε -branched trienediones 4l-n, the slow spontaneous conversion in deuterated chloroform may be due to traces of acid and could be explained by either a steric destabilization effect of the planar polyunsaturated form of substrate 4 exerted by the substituent or a stabilizing effect of the ε -substituent on cyclopentenyl cation intermediate **B**, which would then be tertiary allylic. Some attempts to trap cyclopentenyl cation **B** intermolecularly failed.^{4d} On the other hand, experiments with deuterium -labeled substrates 4u and 4v supported this postulated mechanism (Scheme 3): the products 5u and 5v thus obtained retained the labels, with deuterium atoms located at the expected positions, ruling out either elimination or migration steps.

Table 2. Substrate Scope and Limitations^a



^{*a*}Unless otherwise noted, the reactions were run with the corresponding substrate 4 (0.5 mmol) in CH_2Cl_2 (0.1 M) at reflux using FeCl₃ (0.5 equiv) as the catalyst. ^{*b*}Obtained as a separable mixture of **5c1** and **5c2** in a ratio of 0.6:1. ^{*c*}Obtained as an inseparable mixture of diastereomers. ^{*d*}Obtained via spontaneous isomerization of the substrate in CDCl₃.

Scheme 3. Proposed Mechanism for the Rearrangement and Labeling Experiments



Our results, in agreement with previous experimental observations (Scheme 1A,B), assert that the preferred initial event for 1-oxyheptatrienyl cations involves a five-atom, four-electron process at the end of the linear trienecarbonyl chain, which could be defined as a vinylogous iso-Nazarov path. The fate of the resulting cyclopentenyl cation intermediate, however, is highly dependent on the substrate structure, leading to two formal paths: nucleophilic capture or β -elimination. In connection with advances in Nazarov chemistry, the former can be defined as an interrupted reaction.⁸ Nevertheless, while bicyclo[3.1.0]hexenes result when cyclopentenyl cations are trapped by enolic carbon–carbon double bonds (Scheme 1B),⁹ the flexibility of the trienedicarbonyl system allows a hitherto-unknown outcome in which the enolic oxygen gets involved in the second cyclization step. On the other hand, (2-methylcyclopent-2-enylidene)acetaldehyde can be seen as the "normal" ("not interrupted") product of a vinylogous iso-Nazarov reaction (Scheme 1A).

As stated above, during our studies we verified net stability/ reactivity differences between unsubstituted and alkyl-branched polyenic series. Indeed, when ε -branched compounds **41** and **4m** were subjected to the developed FeCl₃ cycloisomerization protocol, the new tricyclic isomers **61** and **6m** were found as main products instead of the expected **51** and **5m** (Scheme 4). This alternative reaction course, which was found to be more

Scheme 4. Alternative Hard Lewis Acid-Promoted Cycloisomerization Pathway



efficient when an equimolar quantity of $FeCl_3$ was used, provided a new insight into this complex chemistry.

In order to clarify the origin of the observed alternative reaction course, the behavior of alkyl-branched deuterated substrates was examined. As shown in Scheme 5, in the presence of

Scheme 5. Further Deuterium-Labeling Studies and Unified Mechanistic Proposal



iron(III), compounds 4w, 4x, and 4y were isomerized to the corresponding rearranged products 6w, 6x, and 6y, the latter obtained as a mixture of 6y and unlabeled 6l in a 0.15:1 ratio. This substantial loss of deuterium content could be partially prevented (the ratio raised to 1.5:1) when the reaction was conducted in deuterium oxide-saturated CH₂Cl₂. The fact that the deuterium label can be partially lost from substrate 4y clearly suggests different mechanistic routes for the formation of cyclopenta [b] furans of types 5 and 6, considering that compound 4u (Scheme 3), which also bears a label at the end of the polyene chain, did not exhibit any loss upon FeCl3catalyzed rearrangement. It thus became apparent that the formation of isomers 6 may feature an elimination step, and on the basis of these findings a unified mechanistic proposal was elaborated (Scheme 5). After Lewis acid activation, alkyl substitution on ε -branched substrates (R³ = alkyl) could result in a favored canonical structure A for the cyclopentenyl cation

intermediate, which behaves more as a classical trivalent carbenium ion. This cationic center dictates a new tandem reactivity that involves the formation of cyclopentadiene intermediate C, which can be stereoselectively protonated in a 1,4-conjugated fashion to give isomers of type 6, as suggested by the exchange of deuterium with the medium in the case of compound 4y.

In addition, a control experiment showed that when cyclopenta[b]furans **5b** and **5e** were treated with superstoichiometric amounts of iron salt, tricyclic products of type **6** were produced, suggesting that the formation of "normal" or "rerearranged" products could also be associated with the concepts of kinetic and thermodynamic control (Scheme 6).





CONCLUSION

Our results have established an innovative approach for the assembly of cyclopenta[b]furan moieties based on an unusual carbocation chemistry developed from simple conjugated carbonyl polyenes. These studies significantly expand the scope of cationic cascades for the synthesis of five-membered-ring systems. The application of these methodologies beyond dicarbonyl polyene substrates, more detailed mechanistic studies, and the development of asymmetric versions of these transformations will be the focus of future work.

EXPERIMENTAL SECTION

All of the unsaturated aldehydes employed to prepare dicarbonyl substrates 4, except most of the deuterated analogues, are either commercially available or have been previously prepared in the literature.^{10–17} The unsaturated precursors 4a, 4b, 4f, 4i, 4l, 4q, and 5l have been previously prepared by our group.^{5,12} In the NMR data, the labels * and ** indicate that the labeled assignments are exchangeable.

General Procedure for the Preparation of Substrates 4 via Condensation of 1,3-Dicarbonyl Compounds and Unsaturated Aldehydes. A mixture of 1,3-dicarbonyl compound (1 mmol), unsaturated aldehyde (1 mmol, 1 equiv), and 1,2-ethylenediammonium diacetate (EDDA, 36 mg, 0.2 mmol) in CH_2Cl_2 (5.0 mL, 0.2 M) was heated at reflux until the aldehyde substrate was completely consumed (TLC monitoring, approximately 3–4 h). The solvent was then evaporated under reduced pressure, and the residue was purified by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate) to afford the following compounds.

Substrate 4c. An inseparable mixture of diastereomers obtained as an orange solid (164 mg, 75%), mp 140.0 °C (dec.). IR (KBr): 2963, 2928, 1651, 1537, 1366, 1184, 1005 cm^{-1.} ¹H NMR (300 MHz, CDCl₃): δ 7.75–7.52 (overlapping m, 4H), 7.05–6.90 (overlapping dd, 2H), 6.45–6.30 (overlapping m, 2H), 6.28–6.15 (overlapping m, 2H), 2.68–2.61 (overlapping t, 4H), 1.94–1.83 (overlapping m, 10H), 1.22–1.20 (overlapping s, 12H). ¹³C NMR (75 MHz, CDCl₃): δ 203.2 (C), 202.1 (C), 198.9 (C), 197.9 (C), 153.33 (CH), 153.26 (CH), 152.3 (CH), 152.2 (CH), 141.00 (CH), 140.97 (CH), 131.9 (2 × CH), 128.6 (C), 128.5 (C), 127.3 (CH), 127.2 (CH), 42.6 (C), 41.4 (C), 35.8 (CH₂), 34.5 (CH₂), 31.6 (CH₂), 31.5 (CH₂), 24.5 (2 × CH₃), 24.4 (2 × CH₃), 18.7 (2 × CH₃). HRMS (ESI) *m/z*: calcd for C₁₄H₁₈O₂Na [M + Na]⁺ 241.1199, found 241.1190.

Substrate 4d. Obtained as an orange solid (133 mg, 50%), mp 121.5–122.0 °C. IR (KBr): 3061, 3028, 2961, 2905, 1686, 1645, 1570, 1522, 1368, 1238, 1177, 1144, 1026 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.83–7.64 (m, 2H), 7.41–7.18 (m, 5H), 7.11–6.95 (m, 1H), 6.41 (dd, *J* = 14.9 Hz, *J* = 10.9 Hz, 1H), 6.26 (dq, *J* = 14.9 Hz, *J* = 6.7 Hz, 1H), 3.38 (tt, *J* = 11.8 Hz, *J* = 4.0 Hz, 1H), 3.00–2.72 (m, 4H), 1.91 (bd, *J* = 6.5 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 197.9 (C), 196.9 (C), 154.9 (CH), 152.6 (CH), 142.2 (CH), 142.0 (C), 132.2 (CH), 128.7 (2 × CH), 128.3 (C), 127.4 (CH), 126.9 (CH), 126.3 (2 × CH), 47.4 (CH₂), 45.8 (CH₂), 35.6 (CH), 19.0 (CH₃). HRMS (ESI) *m*/*z*: calcd for C₁₈H₁₈O₂Na [M + Na]⁺ 289.1199, found 289.1187.

Substrate **4e**. Obtained as a yellow solid (174 mg, 75%), mp 51.0– 52.0 °C. IR (KBr): 2961, 2951, 2932, 1642, 1576, 1530, 1375, 1237, 1181, 1029 cm^{-1.} ¹H NMR (300 MHz, CDCl₃): δ 7.76–7.62 (m, 2H), 7.09–6.93 (m, 1H), 6.44–6.22 (m, 2H), 2.51 (bs, 4H), 2.25 (bquint, *J* = 7.1 Hz, 2H), 1.11–1.03 (overlapping signals, 9H). ¹³C NMR (75 MHz, CDCl₃): δ 198.7 (C), 197.7 (C), 154.4 (CH), 151.4 (CH), 148.3 (CH), 129.7 (CH), 127.9 (C), 127.6 (CH), 53.8 (CH₂), 52.1 (CH₂), 29.9 (C), 28.4 (2 × CH₃), 26.2 (CH₂), 12.6 (CH₃). HRMS (ESI) *m/z*: calcd for C₁₅H₂₀O₂Na [M + Na]⁺ 255.1355, found 255.1344.

Substrate **4g**. Obtained as a red solid (248 mg, 80%), mp 165.0– 166.0 °C. IR (KBr): 2953, 2934, 1638, 1560, 1522, 1506, 1373, 1240, 1161 cm^{-1.} ¹H NMR (300 MHz, CDCl₃): δ 7.87 (dd, J = 14.1 Hz, J = 12.3 Hz, 1H), 7.71 (d, J = 12.4 Hz, 1H), 7.48–7.40 (m, 2H), 7.17 (ddd, J = 14.2 Hz, J = 9.1 Hz, J = 1.2 Hz, 1H), 7.01–6.86 (m, 4H), 3.83 (s, 3H), 2.52 (bs, 2H), 2.51 (bs, 2H), 1.07 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 198.7 (C), 197.7 (C), 160.8 (C), 154.6 (CH), 151.0 (CH), 142.0 (CH), 129.1 (2 × CH), 128.8 (CH), 128.7 (C), 127.3 (C), 126.3 (CH), 114.3 (2 × CH), 55.2 (CH₃), 53.8 (CH₂), 52.1 (CH₂), 29.9 (C), 28.4 (2 × CH₃). HRMS (ESI) *m/z*: calcd for C₂₀H₂₃O₃ [M + H]⁺ 311.1642, found 311.1638.

Substrate 4h. Obtained as a red solid (253 mg, 85%), mp 140.0– 141.0 °C. IR (KBr): 3049, 2953, 2930, 1684, 1638, 1560, 1516, 1501, 1373, 1225, 1155, 1011 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.89 (dd, *J* = 14.1 Hz, *J* = 12.3 Hz, 1H), 7.70 (d, *J* = 12.3 Hz, 1H), 7.51– 7.43 (m, 2H), 7.21–6.86 (m, 5H), 2.55–2.52 (bs, 4H), 1.08 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 198.8 (C), 197.8 (C), 163.3 (C, d, *J* = 250.9 Hz), 153.2 (CH), 150.4 (CH), 140.3 (CH), 132.2 (C, d, *J* = 3.3 Hz), 129.8 (CH), 129.1 (2 × CH, d, *J* = 8.2 Hz), 128.2 (C), 128.1 (CH, d, *J* = 2.2 Hz), 115.9 (2 × CH, d, *J* = 22.0 Hz), 53.9 (CH₂), 52.2 (CH₂), 30.0 (C), 28.4 (2 × CH₃). HRMS (ESI) *m/z*: calcd for C₁₉H₁₉FO₂Na [M + Na]⁺ 321.1261, found 321.1246.

Substrate **4***j*. Obtained as a yellow solid (228 mg, 95%), mp 89.5–90.0 °C. IR (KBr): 3065, 3030, 2995, 1699, 1645, 1599, 1587, 1558, 1379, 1248, 1151 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.46–7.40 (m, 2H), 7.38–7.24 (m, 3H), 7.13 (d, *J* = 11.6 Hz, 1H), 6.96–6.75 (m, 3H), 6.74–6.60 (m, 1H), 2.38 (s, 3H), 2.36 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 202.8 (C), 196.8 (C), 145.1 (CH), 142.4 (CH), 140.6 (C), 138.9 (CH), 135.9 (C), 128.8 (CH), 128.6 (2 × CH), 127.6 (CH), 127.2 (CH), 126.9 (2 × CH), 31.5 (CH₃), 26.1 (CH₃). HRMS (ESI) *m/z*: calcd for C₁₆H₁₆O₂Na [M + Na]⁺ 263.1042, found 263.1048.

Substrates (2E)-4k and (2Z)-4k. These substrates are unstable compounds; the stereochemistry assignment is based on NOEs. (2E)-4k was obtained as a pale-yellow liquid (73 mg, 35%). IR (film): 2984, 2937, 2915, 1714, 1594, 1371, 1228 cm⁻¹. ¹H NMR (300 MHz, $CDCl_3$): δ 7.31 (d, J = 11.0 Hz, 1H), 6.75–6.56 (m, 2H), 6.27–6.15 (m, 1H), 6.05 (dq, J = 15.1 Hz, J = 6.8 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 2.41 (s, 3H), 1.85 (bdd, J = 6.7 Hz, J = 1.2 Hz, 3H), 1.32 (t, J = 7.1 Hz, 3H). $^{13}\mathrm{C}$ NMR (75 MHz, CDCl_3): δ 200.3, 165.3, 146.2, 145.3, 137.8, 131.3, 130.5, 124.9, 60.8, 31.0, 18.5, 14.0. (2Z)-4k was obtained as a pale-yellow liquid (73 mg, 35%). IR (film): 2984, 2939, 1720, 1688, 1593, 1380, 1220 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.29 (d, J = 11.4 Hz, 1H), 6.80–6.54 (m, 2H), 6.24 (ddq, J = 15.1 Hz, J = 10.3 Hz, J = 1.4 Hz, 1H), 6.08 (dq, J = 15.1 Hz, J = 6.8 Hz, 1H),4.34 (q, J = 7.1 Hz, 2H), 2.36 (s, 3H), 1.87 (bd, J = 6.7 Hz, 3H), 1.37 (t, J = 7.1 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 195.3, 166.3, 146.4, 144.8, 138.1, 131.34, 131.31, 125.0, 61.0, 27.7, 18.6, 14.0.

Substrate 4m. Obtained as a yellow solid (194 mg, 75%), mp 96.0–97.0 °C. IR (KBr): 2947, 2926, 2907, 1684, 1653, 1578, 1541,

1366, 1178 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.78–7.64 (m, 2H), 7.09–6.95 (m, 1H), 6.29 (bt, *J* = 3.6 Hz, 1H), 2.51 (bs, 4H), 2.36– 2.21 (m, 4H), 1.77–1.57 (m, 4H), 1.07 (bs, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 198.8 (C), 197.9 (C), 157.9 (CH), 152.6 (CH), 142.0 (CH), 137.5 (C), 127.6 (C), 122.8 (CH), 53.8 (CH₂), 52.2 (CH₂), 29.9 (C), 28.4 (2 × CH₃), 26.9 (CH₂), 24.2 (CH₂), 21.82 (CH₂), 21.77 (CH₂). HRMS (ESI) *m*/*z*: calcd for C₁₇H₂₂O₂Na [M + Na]⁺ 281.1512, found 281.1508.

Substrate 4n. Obtained as a dark-red solid (239 mg, 80%), mp 121.0–122.0 °C. IR (KBr): 2953, 2922, 1638, 1570, 1520, 1356, 1177 cm^{-1.} ¹H NMR (300 MHz, CDCl₃): δ 7.95 (dd, *J* = 14.4 Hz, *J* = 12.4 Hz, 1H), 7.77 (d, *J* = 12.2 Hz, 1H), 7.15 (d, *J* = 14.6 Hz, 1H), 6.57 (s, 1H), 6.53 (d, *J* = 2.9 Hz, 1H), 6.13 (d, *J* = 2.7 Hz, 1H), 2.52 (s, 4H), 2.37 (s, 3H), 2.24 (s, 3H), 1.08 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 198.9 (C), 197.9 (C), 159.6 (CH), 155.0 (C), 151.8 (CH), 151.4 (C), 132.5 (C), 127.9 (CH), 126.9 (C), 124.9 (CH), 116.6 (CH), 109.1 (CH), 53.9 (CH₂), 52.2 (CH₂), 30.0 (C), 28.4 (2 × CH₃), 13.9 (CH₃), 13.8 (CH₃). HRMS (ESI) *m/z*: calcd for C₁₉H₂₂NaO₃ [M + Na]⁺ 321.1461, found 321.1458.

Substrate **40**. Obtained as a yellow solid (67 mg, 30%), mp 139.0–140.0 °C. IR (KBr): 3022, 2994, 2960, 2933, 1719, 1683, 1599, 1587, 1366, 1219, 991 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 8.00–7.87 (m, 2H), 7.84–7.65 (m, 3H), 7.46 (d, *J* = 12.3 Hz, 1H), 6.95 (dd, *J* = 14.7 Hz, *J* = 10.9 Hz, 1H), 6.42 (dd, *J* = 14.8 Hz, *J* = 10.9 Hz, 1H), 6.23 (dq, *J* = 14.8 Hz, *J* = 6.8 Hz, 1H), 1.91 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 190.2 (C), 189.8 (C), 151.7 (CH), 144.7 (CH), 141.8 (C), 141.2 (CH), 140.5 (C), 134.7 (CH), 134.5 (CH), 131.9 (CH), 126.8 (C), 125.3 (CH), 122.7 (CH), 122.5 (CH), 18.9 (CH₃). HRMS (ESI) *m*/*z*: calcd for C₁₅H₁₂O₂Na [M + Na]⁺ 247.0729, found 247.0721.

Substrate 4p. Obtained as a dark-red solid (54 mg, 20%), mp 189.0 °C (dec.). IR (KBr): 3046, 3005, 2966, 2918, 1661, 1539, 1165 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.86 (dd, J = 14.3 Hz, J = 12.5 Hz, 1H), 7.50–7.40 (m, 3H), 7.30–7.20 (m, 1H), 7.08–6.96 (m, 2H), 6.95–6.86 (m, 2H), 3.85 (s, 3H), 2.68 (s, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 203.7, 203.1, 161.3, 156.3, 148.2, 144.1, 129.5, 128.6, 127.1, 126.2, 126.0, 114.5, 55.3, 34.8, 34.1. HRMS (ESI) *m/z*: calcd for C₁₇H₁₇O₃ [M + H]⁺ 269.1172, found 269.1163.

Substrate **4***r*. Obtained as an orange to red solid (233 mg, 90%), mp 96.5–97.5 °C. IR (KBr): 2953, 2941, 2926, 2868, 1684, 1636, 1607, 1545, 1474, 1354, 1263, 1138, 1020 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 8.15 (dd, *J* = 15.0 Hz, *J* = 12.5 Hz, 1H), 7.74 (d, *J* = 12.5 Hz, 1H), 7.04 (d, *J* = 15.1 Hz, 1H), 6.68 (d, *J* = 3.4 Hz, 1H), 6.15 (d, *J* = 3.3 Hz, 1H), 2.53 (bs, 2H), 2.52 (bs, 2H), 2.39 (s, 3H), 1.08 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 198.7, 197.8, 157.6, 151.11, 151.08, 138.6, 127.4, 122.3, 118.9, 110.0, 53.9, 52.2, 30.0, 28.4, 14.0. HRMS (ESI) *m*/*z*: calcd for C₁₆H₁₉O₃ [M + H]⁺ 259.1329, found 259.1336.

Substrate **4s**. Obtained as an orange solid (214 mg, 60%), mp 140.0 °C (dec.). IR (KBr): 3074, 3055, 3019, 2949, 1684, 1647, 1560, 1555, 1518, 1354, 1234, 1177 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.96 (dd, *J* = 13.3 Hz, *J* = 12.5 Hz, 1H), 7.58 (d, *J* = 12.4 Hz, 1H), 7.47–7.40 (m, 3H), 7.36–7.31 (m, 5H), 7.25–7.18 (m, 2H), 7.15–7.02 (m, 2H), 2.52 (bs, 2H), 2.50 (bs, 2H), 1.07 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 198.8 (C), 197.8 (C), 152.7 (C), 152.1 (CH), 151.0 (CH), 140.8 (C), 138.3 (C), 130.7 (CH), 130.4 (2 × CH), 129.1 (CH), 128.5 (CH), 128.55 (2 × CH), 128.29 (2 × CH), 128.2 (2 × CH), 127.7 (C), 127.5 (CH), 53.9 (CH₂), 52.2 (CH₂), 30.0 (C), 28.4 (2 × CH₃). HRMS (ESI) *m*/*z*: calcd for C₂₅H₂₅O₂ [M + H]⁺ 357.1849, found 357.1838.

Substrate 4t. Obtained as an orange solid (174 mg, 75%), mp 96.0–97.0 °C. IR (KBr): 3057, 2955, 2928, 2903, 1684, 1637, 1570, 1526, 1339, 1238, 1190 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.78–7.63 (m, 2H), 7.40–7.22 (m, 1H), 6.23 (bd, *J* = 11.6 Hz, 1H), 2.51 (s, 4H), 1.94 (bs, 6H), 1.07 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 198.6 (C), 197.8 (C), 152.1 (CH), 150.7 (CH), 149.8 (C), 127.3 (CH), 127.2 (C), 126.5 (CH), 53.8 (CH₂), 52.1 (CH₂), 29.9 (C), 28.4 (2 × CH₃), 26.9 (CH₃), 19.1 (CH₃). HRMS (ESI) *m/z*: calcd for C₁₅H₂₀O₂Na [M + Na]⁺ 255.1350, found 255.1355.

General Procedure for the Rearrangement of Conjugated 1,3-Dicarbonyl Substrates 4. To a solution of dicarbonyl substrate 4 (0.5 mmol) in CH_2Cl_2 (5.0 mL, 0.1 M) was added anhydrous FeCl₃ (41.7 mg, 0.25 mmol, 0.5 equiv). The mixture was refluxed until the dicarbonyl substrate was completely consumed (TLC monitoring; see Tables 1 and 2). The solvent was then evaporated under reduced pressure, and the residue was purified by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate) to afford the following compounds.

Cyclopenta[b]furan 5a.



Obtained as a colorless to pale-yellow solid (84 mg, 88%), mp 46.5–47.0 °C. IR (film): 2961, 2941, 2893, 1640, 1622, 1400, 1179 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 6.02 (dd, J = 5.6 Hz, J = 2.2 Hz, 1H, 2-H), 5.82 (dt, J = 8.6 Hz, J = 1.8 Hz, 1H, 3a-H), 5.74 (dt, J = 5.6 Hz, J = 2.0 Hz, 1H, 3-H), 3.27 (dq, J = 8.5 Hz, J = 1.8 Hz, 1H, 8b-H), 2.84 (qquint, J = 7.3 Hz, J = 1.9 Hz, 1H, 1-H), 2.39 (td, J = 6.4 Hz, J = 1.6 Hz, 2H, 5-H), 2.32 (t, J = 6.3 Hz, 2H, 7-H), 2.00 (quint, J = 6.4 Hz, 2H, 6-H), 1.18 (d, J = 7.3 Hz, 3H, 1-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 195.3 (C, C-8), 175.4 (C, C-4a), 143.9 (CH, C-2), 126.1 (CH, C-3), 117.0 (C, C-8a), 95.1 (CH, C-3), 49.3 (CH, C-8b), 46.5 (CH, C-1), 36.5 (CH₂, C-7), 23.8 (CH₂, C-5), 21.52 (CH₃, C1-CH₃), 21.47 (CH₂, C-6). HRMS (ESI) m/z: calcd for C₁₂H₁₅O₂ [M + H]⁺ 191.1067, found 191.1068.

Cyclopenta[b]furan **5b**. Obtained as a colorless to pale-yellow solid (87 mg, 80%), mp 42.5–43.0 °C. IR (film): 2959, 2910, 2897, 1649, 1634, 1401, 1207, 1037 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 6.02 (dd, J = 5.6 Hz, J = 2.2 Hz, 1H), 5.84 (dt, J = 8.5 Hz, J = 2.0 Hz, 1H), 5.74 (dt, J = 5.6 Hz, J = 2.0 Hz, 1H), 3.29 (dq, J = 8.5 Hz, J = 1.8 Hz, 1H), 2.84 (qquint, J = 7.1 Hz, J = 2.2 Hz, 1H), 2.25 (d, J = 1.6 Hz, 2H), 2.20 (bs, 2H), 1.18 (d, J = 7.3 Hz, 3H), 1.08 (s, 3H), 1.06 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 194.5 (C), 174.2 (C), 143.8 (CH), 126.2 (CH), 115.4 (C), 95.3 (CH), 50.9 (CH₂), 49.0 (CH), 46.4 (CH), 37.6 (CH₂), 33.7 (C), 28.5 (CH₃), 28.3 (CH₃), 21.5 (CH₃). HRMS (ESI) *m*/*z*: calcd for C₁₄H₁₈O₂Na [M + Na]⁺ 241.1199, found 241.1198.

Cyclopenta[b]furans 5c1 and 5c2. These products are regioisomers; their assignment is based on coupling between the carbonyl carbon and the gem-dimethyl groups in the HMBC spectra. 5c1 was obtained as a colorless liquid (35 mg, 32%). IR (film): 2963, 2926, 1651, 1620, 1396, 1159 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 6.00 (ddm, J = 5.6 Hz, J = 2.4 Hz, 1H), 5.79 (dtd, J = 8.5 Hz, J = 2.1 Hz, J = 0.7 Hz, 1H), 5.72 (dt, J = 5.6 Hz, J = 2.0 Hz, 1H), 3.25 (dd, J = 8.5 Hz, J = 1.8 Hz, 1H), 2.82 (qquint, J = 7.0 Hz, J = 2.2 Hz, 1H), 2.37 (bt, J = 6.6 Hz, 2H), 1.80 (bt, J = 6.2 Hz, 2H), 1.21 (s, 3H), 1.16 (d, J = 7.2 Hz, 3H), 1.15 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 194.8 (C), 180.8 (C), 143.6 (CH), 126.0 (CH), 114.6 (C), 94.6 (CH), 49.4 (CH), 46.3 (CH), 36.7 (CH₂), 34.3 (CH₂), 32.4 (C), 24.8 (CH₃), 24.7 (CH₃), 21.5 (CH₃). HRMS (ESI) *m/z*: calcd for C₁₄H₁₉O₂ [M + H]⁺ 219.1380, found 219.1374. 5c2 was obtained as a colorless liquid (58 mg, 53%). IR (film): 2957, 2926, 1632, 1400, 1192 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 5.98 (dd, J = 5.6 Hz, J = 2.2 Hz, 1H), 5.79 (dt, J = 8.7 Hz, J = 2.1 Hz, 1H), 5.71 (dt, J = 5.6 Hz, J = 2.0 Hz, 1H), 3.21 (dq, *J* = 8.5 Hz, *J* = 1.5 Hz, 1H), 2.75 (qquint, *J* = 7.0 Hz, *J* = 2.0 Hz, 1H), 2.38 (tm, J = 6.4 Hz, 2H), 1.80 (t, J = 6.3 Hz, 2H), 1.15 (d, J = 7.0 Hz, 3H), 1.08 (s, 3H), 1.06 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 200.3 (C), 173.2 (C), 144.0 (CH), 126.2 (CH), 115.2 (C), 95.3 (CH), 49.5 (CH), 46.7 (CH), 40.5 (C), 35.5 (CH₂), 24.3 (2 × CH₃), 21.44 (CH₃), 21.39 (CH₂). HRMS (ESI) m/z: calcd for $C_{14}H_{19}O_2 [M + H]^+$ 219.1380, found 219.1383.

Cyclopenta[*b*]*furans* **5***d*. Obtained as a colorless solid (106 mg, 80%), mp 70.0–71.0 °C. The diastereomeric ratio could not be determined because all of the signals overlap. IR (KBr): 3059, 3028, 2955, 2922, 1647, 1628, 1400, 1198, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.37–7.29 (overlapping m, 4H), 7.28–7.20 (overlapping m, 6H), 6.08–6.02 (overlapping m, 2H), 5.92–5.84 (overlapping m, 2H),

5.80–5.72 (overlapping m, 2H), 3.47–3.27 (overlapping m, 4H), 2.95–2.83 (overlapping m, 2H), 2.67–2.54 (overlapping m, 8H), 1.23–1.17 (overlapping m, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 193.8 (C), 193.7 (C), 174.7 (C), 174.6 (C), 144.0 (CH, CH), 142.6 (C, C), 128.6 (2 × CH, 2 × CH), 126.8 (CH, CH), 126.6 (2 × CH, 2 × CH), 126.2 (CH), 126.0 (CH), 117.1 (C), 116.6 (C), 95.8 (CH), 95.6 (CH), 49.20 (CH), 49.17 (CH), 46.8 (CH), 46.1 (CH), 44.1 (CH₂), 43.7 (CH₂), 40.3 (CH), 40.0 (CH), 31.45 (CH₂), 31.39 (CH₂), 21.6 (CH₃), 21.5 (CH₃). HRMS (ESI) m/z: calcd for C₁₈H₁₈O₂Na [M + Na]⁺ 289.1199, found 289.1186.

Cyclopenta[b]furan **5e**. Obtained as a colorless liquid (93 mg, 80%). IR (film): 2960, 2931, 1653, 1632, 1401, 1202, 1039 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 6.09–6.01 (m, 1H), 5.84–5.74 (m, 2H), 3.34 (dm, *J* = 8.4 Hz, 1H), 2.81–2.71 (m, 1H), 2.24 (bs, 2H), 2.19 (bs, 2H), 1.67–1.38 (m, 2H), 1.08 (bs, 3H), 1.06 (bs, 3H), 0.96 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 194.4 (C), 174.2 (C), 141.7 (CH), 127.0 (CH), 115.3 (C), 95.0 (CH), 52.9 (CH), 51.0 (CH₂), 46.9 (CH), 37.7 (CH₂), 33.7 (C), 28.7 (CH₂), 28.6 (CH₃), 28.3 (CH₃), 11.3 (CH₃). HRMS (ESI) *m/z*: calcd for C₁₅H₂₀O₂Na [M + Na]⁺ 255.1355, found 255.1353.

Cyclopenta[b]furan **5f**. Obtained as a pale-yellow liquid (119 mg, 85%). IR (film): 3061, 3028, 2959, 2929, 1630, 1401 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.33–7.28 (m, 4H), 7.25–7.17 (m, 1H), 6.15 (dd, *J* = 5.7 Hz, *J* = 2.4 Hz, 1H), 6.02 (dt, *J* = 5.7 Hz, *J* = 2.0 Hz, 1H), 5.94 (bdt, *J* = 8.4 Hz, *J* = 2.2 Hz, 1H), 4.09 (quint, *J* = 2.1 Hz, 1H), 3.58 (dq, *J* = 8.3 Hz, *J* = 1.7 Hz, 1H), 2.29 (bs, 2H), 2.25 (bs, 2H), 1.11 (s, 3H), 1.09 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 194.4 (C), 174.3 (C), 143.5 (C), 139.8 (CH), 129.0 (CH), 128.4 (2 × CH), 127.2 (2 × CH), 126.4 (CH), 115.2 (C), 95.0 (CH), 56.7 (CH), 2 × 51.1 (CH, CH₂), 37.8 (CH₂), 33.9 (C), 28.7 (CH₃), 28.3 (CH₃). HRMS (ESI) *m*/*z*: calcd for C₁₉H₂₀O₂Na [M + Na]⁺ 303.1355, found 303.1354.

Cyclopenta[b]furan **5***g*. Obtained as a pale-yellow solid (132 mg, 85%), mp 109.5–110.5 °C. IR (KBr): 3069, 3003, 2951, 1632, 1508, 1398, 1244, 1030 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.25–7.18 (m, 2H), 6.88–6.81 (m, 2H), 6.13 (ddm, *J* = 5.6 Hz, *J* = 2.3 Hz, 1H), 6.00 (dt, *J* = 5.6 Hz, *J* = 2.0 Hz, 1H), 5.92 (dm, *J* = 8.5 Hz, 1H), 4.03 (quint, *J* = 2.0 Hz, 1H), 3.78 (s, 3H), 3.52 (dm, *J* = 8.5 Hz, 1H), 2.28 (bs, 2H), 2.24 (s, 2H), 1.10 (s, 3H), 1.09 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 194.4 (C), 174.2 (C), 158.1 (C), 140.0 (CH), 135.6 (C), 128.6 (CH), 128.1 (2 × CH), 115.2 (C), 113.7 (2 × CH), 95.0 (CH), 55.9 (CH), 55.1 (CH₃), 51.2 (CH), 51.0 (CH₂), 37.7 (CH₂), 33.8 (C), 28.6 (CH₃), 28.3 (CH₃). HRMS (ESI) *m*/*z*: calcd for C₂₀H₂₂O₃K [M + K]⁺ 349.1200, found 349.1192.

Cyclopenta[b]furan 5h.



Obtained as a colorless liquid (112 mg, 75%). IR (film): 2957, 2930, 1632, 1506, 1402, 1221 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.32–7.23 (m, 2H, Ar–H), 7.03–6.93 (m, 2H, Ar–H), 6.13 (bdd, *J* = 5.7 Hz, *J* = 2.4 Hz, 1H, 2-H), 6.03 (dt, *J* = 5.7 Hz, *J* = 1.9 Hz, 1H, 3-H), 5.92 (dm, *J* = 8.3 Hz, 1H, 3a-H), 4.05 (quint, *J* = 2.0 Hz, 1H, 1-H), 3.52 (dq, *J* = 8.3 Hz, *J* = 1.7 Hz, 1H, 8b-H), 2.29 (d, *J* = 1.5 Hz, 2H, 5-H), 2.25 (s, 2H, 7-H), 1.10 (s, 3H, 6-CH₃), 1.09 (s, 3H, 6-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 194.4 (C, C-8), 174.4 (C, C-4a), 161.5 (C, d, *J* = 244.8 Hz, C–F), 139.6 (CH, C-2), 139.2 (C, d, *J* = 2.7 Hz, Ar), 129.2 (CH, C-3), 128.2 (2 × CH, d, *J* = 7.7 Hz, Ar), 115.1 (C, C-8a), 115.0 (2 × CH, d, *J* = 20.9 Hz, Ar), 94.9 (CH, C-3a), 56.0 (CH, C-1), 51.2 (CH, C-8b), 51.0 (CH₂, C-7), 37.7 (CH₂, C-5), 33.9 (C, C-6), 28.6 (CH₃, C6-CH₃), 28.3 (CH₃, C6-CH₃). HRMS (ESI) *m/z*: calcd for C₁₉H₂₀FO₂ [M + H]⁺ 299.1442, found 299.1443.

Cyclopenta[b]furan **5***i*. Obtained as a colorless liquid (49 mg, 55%). IR (film): 2957, 2926, 1666, 1614, 1587, 1379, 1205 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 6.00 (dm, J = 5.5 Hz, 1H), 5.73 (dm, J = 5.7 Hz, 1H), 5.65 (dm, J = 9.0 Hz, 1H), 3.38 (dm, J = 9.0 Hz, 1H), 2.74 (qquint, J = 7.1 Hz, J = 2.2 Hz, 1H), 2.25 (bs, 3H), 2.19 (bs, 3H),

1.18 (d, J = 7.1 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 194.3 (C), 166.5 (C), 143.0 (CH), 126.9 (CH), 117.3 (C), 91.5 (CH), 53.0 (CH), 48.3 (CH), 29.3 (CH₃), 21.6 (CH₃), 15.2 (CH₃). HRMS (ESI) m/z: calcd for C₁₁H₁₄O₂Na [M + Na]⁺ 201.0886, found 201.0883.

Cyclopenta[b]furan **5***j*. Obtained as a pale-yellow liquid (48 mg, 40%). IR (film): 3030, 2957, 1655 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.36–7.28 (m, 2H), 7.27–7.17 (m, 3H), 6.06 (bdd, *J* = 5.6 Hz, *J* = 2.2 Hz, 1H), 5.97 (dt, *J* = 5.6 Hz, *J* = 1.9 Hz, 1H), 5.79 (bd, *J* = 8.8 Hz, 1H), 3.94 (quint, *J* = 1.9 Hz, 1H), 3.74 (bd, *J* = 8.8 Hz, 1H), 2.23 (overlapping signals, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 194.2, 166.6, 143.4, 140.0, 128.8, 128.5, 127.3, 126.5, 117.1, 91.4, 59.0, 55.0, 29.6, 15.3. HRMS (ESI) *m/z*: calcd for C₁₆H₁₆O₂Na [M + Na]⁺ 263.1042, found 263.1051.

Cyclopenta[b]furan **5***k*. Obtained as a colorless liquid (26 mg, 25%). IR (film): 2958, 2927, 1701, 1640, 1381, 1204, 1081 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 6.00 (ddd, J = 5.6 Hz, J = 2.3 Hz, J = 0.6 Hz, 1H), 5.73 (dt, J = 5.6 Hz, J = 2.0 Hz, 1H), 5.65 (dtd, J = 8.9 Hz, J = 2.2 Hz, J = 0.8 Hz, 1H), 4.27–4.09 (m, 2H), 3.31 (dm, J = 8.9 Hz, 1H), 2.80 (qquint, J = 7.1 Hz, J = 2.2 Hz, 1H), 2.17 (d, J = 1.4 Hz, 3H), 1.30 (t, J = 7.0 Hz, 3H), 1.15 (d, J = 7.1 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 166.8 (C), 166.3 (C), 143.1 (CH), 127.0 (CH), 106.1 (C), 91.6 (CH), 59.2 (CH₂), 52.4 (CH), 48.3 (CH), 21.4 (CH₃), 14.3 (CH₃), 14.1 (CH₃). HRMS (ESI) *m*/*z*: calcd for C₁₂H₁₇O₃ [M + H]⁺ 209.1172, found 209.1168.

Spontaneous Cycloisomerization of Compounds 4m and 4n in CDCl₃. Cyclopenta[b]furan 5m.



Leaving compound 4m (77 mg, 0.3 mmol) in CDCl₃ for 2 weeks at room temperature afforded compound 5m as a colorless to pale-yellow solid in 65% yield (50 mg) after flash column chromatography (silica gel, eluting with petroleum ether/ethyl acetate). Mp: 98.0-99.0 °C. IR (KBr): 2922, 2851, 1647, 1624, 1404, 1213, 1032 cm⁻¹. ¹H NMR (300 MHz, $CDCl_3$: δ 5.72 (dtd, J = 8.8 Hz, J = 2.2 Hz, J = 0.6 Hz, 1H, 5a-H), 5.42 (q, J = 1.8 Hz, 1H, 6-H), 3.31 (dq, J = 8.8 Hz, J = 1.8 Hz, 1H, 10b-H), 2.50 (dm, J = 13.2 Hz, 1H, 7-H_{β}), 2.42–2.31 (m, 2H, 10a-H, 10-H_a), 2.25 (d, J = 1.3 Hz, 2H, 4-H), 2.20 (s, 2H, 2-H), 1.97 (btd, J = 13.2 Hz, J = 5.4 Hz, 1H, 7-H_{α}), 1.90–1.79 (m, 1H, 8-H_{α}), 1.79–1.69 (m, 1H, 9-H_{β}), 1.37 (qt, $J = 13.3 \text{ Hz}, J = 3.3 \text{ Hz}, 1\text{H}, 9\text{-H}_{\alpha}$, 1.17 (qt, J = 12.9 Hz, J = 3.8 HzHz, 1H, 8-H_{β}), 1.08 (s, 3H, 3-CH₃), 1.07 (s, 3H, 3-CH₃), 0.98 (qd, J = 13.1 Hz, J = 3.4 Hz, 1H, 10-H_{β}). ¹³C NMR (75 MHz, CDCl₃): δ 194.5 (C, C-1), 174.8 (C, C-4a), 156.5 (C, C-6a), 117.4 (CH, C-6), 115.7 (C, C-10c), 95.5 (CH, C-5a), 52.6 (CH, C-10a), 50.9 (CH₂, C-2), 48.0 (CH, C-10b), 37.8 (CH₂, C-4), 35.7 (CH₂, C-10), 33.7 (C, C-3), 29.1 (CH₂, C-7), 28.6 (CH₃, C3-CH₃), 28.4 (CH₃, C3-CH₃), 27.3 (CH₂, C-8), 25.5 (CH₂, C-9). HRMS (ESI) m/z: calcd for C₁₇H₂₃O₂ [M + H]⁺ 259.1693, found 259.1688.

Cyclopenta[b]furan **5n**. Leaving compound **4n** (60 mg, 0.2 mmol) in CDCl₃ for 2 months at room temperature afforded compound **5n** as a colorless to pale-yellow liquid in 60% yield (36 mg) after flash column chromatography (silica gel, eluting with petroleum ether/ethyl acetate). IR (film): 2957, 2920, 1620, 1402, 1215 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 6.00 (d, J = 2.9 Hz, 1H), 5.89 (dm, J = 8.2 Hz, 1H), 5.85 (d, J = 2.2 Hz, 1H), 5.58–5.54 (m, 1H), 3.84 (bs, 1H), 3.78 (bd, J = 8.3 Hz, 1H), 2.27 (bs, 2H), 2.25–2.19 (overlapping signals, SH), 1.69 (s, 3H), 1.09 (s, 3H), 1.07 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 194.3 (C), 174.7 (C), 153.3 (C), 150.8 (C), 148.1 (C), 123.8 (CH), 114.7 (C), 106.6 (CH), 105.9 (CH), 95.0 (CH), 53.5 (CH), 51.0 (CH₂), 48.7 (CH), 37.8 (CH₂), 33.8 (C), 28.9 (CH₃),

28.2 (CH₃), 15.2 (CH₃), 13.5 (CH₃). HRMS (ESI) m/z: calcd for C₁₉H₂₂NaO₃ [M + Na]⁺ 321.1461, found 321.1467.

Deuterium Labeling Experiments: Substitution at Unbranched Dienal C-5.



Ester S1. To a solution of ethyl diethylphosphonoacetate (1.35 mL, 6.8 mmol) in THF (14.0 mL) at 0 °C was added potassium tertbutoxide (0.94 g, 7.8 mmol). The mixture was stirred for 30 min at 0 °C, and then cinnamaldehyde-3-d¹⁸ (0.89 g, 6.7 mmol) in THF (2.0 mL) was added. The mixture was stirred for 1 h at room temperature. The reaction was quenched with water, and the resulting mixture was extracted three times with Et₂O. The combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure. Flash column chromatography (silica gel, eluting with petroleum ether) afforded ester S1 as a colorless liquid (1.16 g, 85% yield). IR (film): 3057, 3022, 2980, 2227, 1707, 1624, 1258, 1138 $\rm cm^{-1}.~^1H~NMR$ (300 MHz, CDCl₃): δ 7.51-7.24 (overlapping signals, 6H), 6.87 (bd, J = 11.2 Hz, 1H), 5.99 (d, J = 15.4 Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 1.32 (t, J = 7.1 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 167.0, 144.4, 135.9, 128.9, 128.7, 127.0, 126.0, 121.2, 60.2, 14.2, CD signal missing. HRMS (ESI) m/z: calcd for C₁₃H₁₃DO₂Na [M + Na]⁺ 226.0949, found 226.0956.

Aldehyde S2. To a suspension of lithium aluminum hydride (0.10 g, 2.60 mmol) in Et₂O (4.5 mL) at 0 °C was added dropwise a solution of ester S1 (0.45 g, 2.23 mmol) in Et₂O (2.4 mL). The mixture was stirred for 1 h at room temperature and then cooled to 0 °C. The mixture was then treated dropwise with an aqueous sodium hydroxide solution (0.45 g of NaOH in 0.45 mL of H2O). After being stirred for 30 min, the mixture was diluted with Et₂O, filtered through Celite (Et₂O wash), and concentrated under reduced pressure. The residue was then dissolved in CH_2Cl_2 (4 mL) and hexanes (4 mL). To this stirred solution was added activated MnO₂ (1.84 g, 19 mmol). The reaction mixture was stirred for 4 h at room temperature and then filtered through Celite. The solid residue was washed with 30% ethyl acetate in hexanes solution. The combined filtrates were dried (Na₂SO₄) and concentrated under reduced pressure. Flash column chromatography of the residue (silica gel, eluting with 9:1 hexanes/ ethyl acetate) afforded aldehyde S2 as a pale-yellow liquid in 50% yield (177 mg) over two steps. IR (film): 3050, 3028, 2820, 2743, 2232, 1616, 1167, 1119 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 9.61 (d, J = 7.9 Hz, 1H), 7.54-7.44 (m, 2H), 7.42-7.30 (m, 3H), 7.25 (dd, J = 15.1 Hz, J = 11.1 Hz, 1H), 6.98 (bd, J = 11.0 Hz, 1H), 6.25 (dd, J = 15.1 Hz, J = 7.9 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 193.3 (CH), 151.8 (CH), 141.9 (CD, t, J = 23.3 Hz), 135.3 (C), 131.4 (CH), 129.5 (CH), 128.7 (2 × CH), 127.3 (2 × CH), 125.9 (CH). HRMS (ESI) m/z: calcd for C₁₁H₉DONa [M + Na]⁺ 182.0687, found 182.0678.

Substrate 4u. Obtained in 80% yield (225 mg) as an orange to red solid using the general condensation protocol. Mp: 116.5–117.5 °C. IR (KBr): 3055, 3026, 2949, 2922, 1686, 1647, 1566, 1528, 1375, 1229 cm^{-1.} ¹H NMR (300 MHz, CDCl₃): δ 7.90 (dd, *J* = 13.9 Hz, *J* = 12.3 Hz, 1H, 2'-H), 7.70 (d, *J* = 12.3 Hz, 1H, 1'-H), 7.52–7.44 (m, 2H, Ar–H), 7.40–7.25 (m, 3H, Ar–H), 7.23–7.02 (m, 2H, 3'-H, 4'-H), 2.524 (bs, 2H, 4-H*), 2.519 (bs, 2H, 6-H*), 1.07 (s, 6H, 5-CH₃, 5-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 198.7 (C, C-1*), 197.6 (C, C-3*), 153.4 (CH, C-3'), 150.4 (CH, C-1'), 141.4 (CD, t, *J* = 23.5 Hz, C-5'), 135.8 (C, Ar), 129.7 (CH, C-2'), 129.3 (CH, Ar), 128.7 (2 × CH, Ar), 128.2 (CH, C-4'), 128.0 (C, C-2), 127.3 (2 × CH, Ar), 53.8 (CH₂, C-4**), 52.1 (CH₂, C-6**), 29.9 (C, C-5), 28.3 (2 × CH₃, C5-CH₃). HRMS (ESI) *m/z*: calcd for C₁₉H₂₀DO₂ [M + H]⁺ 282.1599, found 282.1609.

Cyclopenta[b]furan **5***u*. Obtained as a pale-yellow liquid in 75% yield (106 mg) using the general cycloisomerization protocol with FeCl₃ (0.5 equiv). IR (film): 3055, 3024, 2957, 1647, 1630, 1398, 1217 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.34–7.26 (m, 4H, Ar–H), 7.25–7.16 (m, 1H, Ar–H), 6.14 (bd, *J* = 5.7 Hz, 1H, 2-H), 6.02 (dd, *J* = 5.7 Hz, *J* = 1.9 Hz, 1H, 3-H), 5.93 (dm, *J* = 8.4 Hz, 1H, 3a-H), 3.57 (dt, *J* = 8.3 Hz, *J* = 1.7 Hz, 1H, 8b-H), 2.29 (bd, *J* = 1.4 Hz, 2H, 5-H), 2.25 (bs, 2H, 7-H), 1.11 (s, 3H, 6-CH₃), 1.09 (s, 3H, 6-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 194.4 (C, C-8), 174.3 (C, C-4a), 143.4 (C, Ar), 139.8 (CH, C-2), 129.0 (CH, C-3), 128.4 (2 × CH, Ar), 127.2 (2 × CH, Ar), 126.4 (CH, Ar), 115.2 (C, C-8a), 95.0 (CH, C-3a), 56.3 (CD, t, *J* = 21.0 Hz, C-1), 51.1 (CH₂, C-7), 51.0 (CH, C-8b), 37.8 (CH₂, C-5), 33.9 (C, C-6), 28.7 (CH₃, 6-CH₃), 28.3 (CH₃, 6-CH₃). HRMS (ESI) *m*/*z*: calcd for C₁₉H₂₀DO₂ [M + H]⁺ 282.1599, found 282.1601.

Deuterium Labeling Experiments: Substitution at Unbranched Dienal C-1.



Aldehyde S3. To a suspension of lithium aluminum deuteride (0.11 g, 2.6 mmol) in Et₂O (4.5 mL) at 0 °C was added dropwise a solution of ethyl (2E,4E)-5-phenylpenta-2,4-dienoate¹⁹ (0.45 g, 2.25 mmol) in Et₂O (2.4 mL). The mixture was stirred for 15 min at room temperature and then cooled to 0 °C. The mixture was then treated dropwise with an aqueous sodium hydroxide solution (0.45 g of NaOH in 0.45 mL of H₂O). After being stirred for 30 min, the mixture was diluted with Et₂O, filtered through Celite (Et₂O wash), and concentrated under reduced pressure. The residue was then dissolved in CH₂Cl₂ (4 mL) and hexanes (4 mL). To this stirred solution was added activated MnO₂ (1.84 g, 19 mmol). The reaction mixture was stirred for 2 h at room temperature and then filtered through Celite. The solid residue was washed with 30% ethyl acetate in hexanes solution. The combined filtrates were dried (Na2SO4) and concentrated under reduced pressure. Flash column chromatography of the residue (silica gel, eluting with 9.8:0.2 hexanes/ethyl acetate) afforded aldehyde S3 as a pale-yellow liquid (0.108 g, 0.68 mmol, 30% yield over two steps). IR (film): 3057, 3028, 2997, 2073, 1670, 1649, 1620, 1151 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.52–7.46 (m, 2H), 7.41-7.30 (m, 3H), 7.24 (ddd, J = 15.1 Hz, J = 7.3 Hz, J = 3.2 Hz, 1H), 7.04–6.91 (m, 2H), 6.25 (bd, J = 15.1 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 193.0 (CD, t, J = 26.3 Hz), 151.8, 142.2, 135.3, 131.3, 129.4, 128.7, 127.3, 126.0. HRMS (ESI) m/z: calcd for C₁₁H₁₀DO [M + H]⁺ 160.0867, found 160.0864.

Substrate **4v**. Obtained in 75% yield (211 mg) as an orange solid using the general condensation protocol. Mp: 119.5–120.5 °C. IR (KBr): 3055, 3026, 2949, 1686, 1647, 1516, 1234 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.89 (d, J = 14.1 Hz, 1H, 2'-H), 7.51–7.46 (m, 2H, Ar–H), 7.41–7.29 (m, 3H, Ar–H), 7.23–7.02 (m, 2H, 3'-H, 4'-H), 6.94 (d, J = 14.8 Hz, 1H, 5'-H), 2.53 (bs, 2H, 4-H*), 2.52 (bs, 2H, 6-H*), 1.08 (s, 6H, 5-CH₃, 5-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 198.8 (C, C-1*), 197.7 (C, C-3*), 153.5 (CH, C-3'), 150.1 (CD, t, J = 23.6 Hz, C-1'), 141.8 (CH, C-5'), 135.9 (C, Ar), 129.7 (CH, C-2'), 129.4 (CH, Ar), 128.8 (2 × CH, Ar), 128.3 (CH, C-4'), 128.0 (C, C-2), 127.4 (2 × CH, Ar), 53.9 (CH₂, C-4**), 52.2 (CH₂, C-6**), 29.9 (C, C-5), 28.4 (2 × CH₃, C5-CH₃). HRMS (ESI) m/z: calcd for C₁₉H₁₉DO₂Na [M + Na]⁺ 304.1418, found 304.1413.

Cyclopenta[*b*]*furan* **5v**. Obtained as a pale-yellow to colorless liquid in 80% yield (113 mg) using the general cycloisomerization

protocol. IR (film): 3059, 2957, 1632, 1396, 1221, 1099 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.34–7.26 (m, 4H, Ar–H), 7.24–7.16 (m, 1H, Ar–H), 6.14 (bdd, *J* = 5.7 Hz, *J* = 2.4 Hz, 1H, 2-H), 6.01 (dt, *J* = 5.7 Hz, *J* = 2.0 Hz, 1H, 3-H), 5.94–5.90 (m, 1H, 3a-H), 4.07 (q, *J* = 2.1 Hz, 1H, 1-H), 2.28 (s, 2H, 5-H), 2.24 (bs, 2H, 7-H), 1.10 (s, 3H, 6-CH₃), 1.08 (s, 3H, 6-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 194.4 (C, C-8), 174.3 (C, C-4a), 143.4 (C, Ar), 139.8 (CH, C-2), 128.9 (CH, C-3), 128.3 (2 × CH, Ar), 127.1 (2 × CH, Ar), 126.4 (CH, Ar), 115.0 (C, C-8a), 94.9 (CH, C-3a), 56.6 (CH, C-1), 51.0 (CH₂, C-7), 50.7 (CD, t, *J* = 21.5 Hz, C-8b), 37.7 (CH₂, C-5), 33.8 (C, C-6), 28.6 (CH₃, C6-CH₃), 28.3 (CH₃ - C6-CH₃). HRMS (ESI) *m*/*z*: calcd for C₁₉H₁₉DO₂Na [M + Na]⁺ 304.1418, found 304.1415.

Rearrangement of Branched Conjugated 1,3-Dicarbonyl Substrates Using FeCl₃. *Cyclopenta[b]furan 6l.*



Obtained as a colorless solid in 60% yield (88 mg) using the general cycloisomerization protocol (1 equiv of FeCl₃). Mp: 84.5-85.5 °C. IR (KBr): 3057, 3036, 2957, 2926, 1632, 1398, 1236 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.39–7.32 (m, 2H, Ar–H), 7.30–7.21 (m, 3H, Ar-H), 5.73-5.70 (m, 1H, 2-H), 3.66 (dq, J = 7.7 Hz, J = 1.6 Hz, 1H, 8b-H), 2.86 (ddquint, J = 17.3 Hz, J = 7.7 Hz, J = 2.4 Hz, 1H, 1-H_{β}), 2.53 (dh, J = 17.3 Hz, J = 2.0 Hz, 1H, 1-H_a), 2.40 (bs, 2H, 5-H), 2.24 (dAB, J = 16.2 Hz, 1H, 7-H), 2.22 (dAB, J = 16.2 Hz, 1H, 7-H), 1.59 $(td, J = 2.0 Hz, J = 1.8 Hz, 3H, 3-CH_3), 1.12 (s, 6H, 6-CH_3, 6-CH_3).$ ¹³C NMR (75 MHz, CDCl₃): δ 194.8 (C, C-8), 173.9 (C, C-4a), 141.8 (C, Ar), 139.5 (C, C-3), 129.9 (CH, C-2), 128.5 (2 × CH, Ar), 127.5 (CH, Ar), 124.4 (2 × CH, Ar), 115.9 (C, C-8a), 107.8 (C, C-3a), 51.2 (CH₂, C-7), 50.5 (CH, C-8b), 38.0 (CH₂, C-5), 37.0 (CH₂, C-1), 34.1 (C, C-6), 28.9 (CH₃, C6-CH₃), 28.5 (CH₃, C6-CH₃), 12.0 (CH₃, C3-CH₃). HRMS (ESI) m/z: calcd for C₂₀H₂₂O₂Na [M + Na]⁺ 317.1512, found 317.1504.

Cyclopenta[b]furan 6m.



Obtained as a pale-yellow liquid in 85% yield (110 mg) using the general cycloisomerization protocol (1 equiv of FeCl₃). IR (film): 2934, 2860, 1649, 1624, 1402, 1234, 1140 $\rm cm^{-1}.$ $^1\rm H$ NMR (300 MHz, $CDCl_3$): δ 5.42 (q, J = 2.0 Hz, 1H, 5-H), 3.32 (dq, J = 8.0 Hz, J =1.8 Hz, 1H, 6a-H), 2.70 (ddt, J = 17.1 Hz, J = 8.1 Hz, J = 2.3 Hz, 1H, $6-H_{\beta}$), 2.48–2.28 (m, 2H, $6-H_{\alpha}$, 4-H), 2.26 (d, J = 1.4 Hz, 2H, 10-H), 2.24–2.06 (m, 2H, 1-H_a, 4-H), 2.20 (bs, 2H, 8-H), 1.93–1.66 (m, 3H, $2-H_{\alpha}$, $2-H_{\beta}$, $3-H_{\alpha}$), 1.51 (td, J = 13.4 Hz, J = 4.6 Hz, 1H, $1-H_{\beta}$), 1.29 $(qt, J = 13.1 Hz, J = 4.1 Hz, 1H, 3-H_{\beta}), 1.09 (s, 3H, 9-CH_3), 1.07$ (s, 3H, 9-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 194.8 (C, C-7), 174.3 (C, C-10a), 141.3 (C, C-4a), 124.8 (CH, C-5), 115.8 (C, C-6b), 104.6 (C, C-11a), 50.8 (CH₂, C-8), 45.1 (CH, C-6a), 37.9 (CH₂, C-10), 37.3 (CH₂, C-6), 36.9 (CH₂, C-1), 33.7 (C, C-9), 28.5 (CH₃, C9-CH₃), 28.4 (CH₃, C9-CH₃), 26.5 (CH₂, C-3), 26.0 (CH₂, C-4), 22.1 (CH₂, C-2). HRMS (ESI) m/z: calcd for $C_{17}H_{23}O_2$ [M + H]⁺ 259.1693, found 259.1688.

Deuterium Labeling Experiments: Substitution at Branched Dienal C-1.



Aldehyde **54**. Obtained as a pale-yellow solid in 55% yield (0.214 g over two steps) from (2*E*,4*E*)-4-methyl-5-phenylpenta-2,4-dienoate¹⁹ (0.487 g, 2.25 mmol) using the same reduction/oxidation protocol as for the preparation of aldehyde **S3**. Mp: 39.5–40.5 °C. IR (KBr): 3055, 3022, 2992, 2947, 2918, 2093, 1662, 1605, 1151 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.44–7.25 (m, 6H), 6.94 (bs, 1H), 6.27 (d, *J* = 15.5 Hz, 1H), 2.08 (d, *J* = 1.2 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 193.3 (CD, t, *J* = 26.4 Hz), 157.6, 140.5, 136.0, 134.2, 129.4, 128.2, 128.0, 127.9 (CHCD, t, *J* = 3.8 Hz), 13.6. HRMS (ESI) *m/z*: calcd for C₁₂H₁₂DO [M + H]⁺ 174.1023, found 174.1019.

Substrate 4w. Obtained in 85% yield (251 mg) as an orange solid using the general condensation protocol. Mp: 114.5–115.0 °C. IR (KBr): 2951, 2924, 1645, 1516, 1331, 1111 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.93 (d, *J* = 15.1 Hz, 1H, 2'-H), 7.41–7.26 (m, SH, Ar–H), 7.22 (dd, *J* = 15.1 Hz, *J* = 0.8 Hz, 1H, 3'-H), 6.90 (bs, 1H, 5'-H), 2.53 (bs, 4H, 4-H, 6-H), 2.18 (d, *J* = 1.1 Hz, 3H, 4'-CH₃), 1.08 (s, 6H, 5-CH₃, 5-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 198.9 (C, C-1*), 197.8 (C, C-3*), 159.3 (CH, C-3'), 151.1 (CD, t, *J* = 23.7 Hz, C-1'), 141.0 (CH, C-5'), 136.45 (C, Ar), 136.37 (C, C-4'), 129.6 (2 × CH, Ar), 128.3 (2 × CH, Ar), 128.1 (CH, Ar), 127.9 (C, C-2), 125.4 (CH, C-2'), 53.9 (CH₂, C-4**), 52.2 (CH₂, C-6**), 30.0 (C, C-5), 28.4 (2 × CH₃, C5-CH₃), C5-CH₃), 13.9 (CH₃, C4'-CH₃). HRMS (ESI) *m/z*: calcd for C₂₀H₂₂DO₂Na [M + Na]⁺ 296.1755, found 296.1760.

Cvclopenta[b]furan 6w. Obtained as a colorless solid in 73% yield (108 mg) using the general cycloisomerization protocol (1 equiv of FeCl₃). Mp: 92.0-93.0 °C. IR (film): 3061, 2957, 2924, 2193, 1645, 1628, 1600, 1394, 1219, 1092 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.40-7.31 (m, 2H, Ar-H), 7.30-7.20 (m, 3H, Ar-H), 5.75-5.68 (m, 1H, 2-H), 2.85 (dquint, J = 17.2 Hz, J = 2.2 Hz, 1H, 1-H_{β}), 2.52 (dquint, J = 17.3 Hz, J = 2.1 Hz, 1H, 1-H_a), 2.41 (bs, 2H, 5-H), 2.23 (dAB, J = 16.4 Hz, 1H, 7-H), 2.22 (dAB, J = 16.4 Hz, 1H, 7-H), 1.59 $(bq, J = 1.6 Hz, 3H, 3-CH_3), 1.12 (s, 6H, 6-CH_3, 6-CH_3).$ ¹³C NMR (75 MHz, CDCl₃): δ 194.7 (C, C-8), 173.8 (C, C-4a), 141.5 (C, Ar), 139.3 (C, C-3), 129.7 (CH, C-2), 128.4 (2 × CH, Ar), 127.3 (CH, Ar), 124.2 (2 × CH, Ar), 115.7 (C, C-8a), 107.5 (C, C-3a), 51.0 (CH₂, C-7), 50.0 (CD, t, J = 20.6 Hz, C-8b), 37.8 (CH₂, C-5), 36.7 (CH₂, C-1), 33.9 (C, C-6), 28.7 (CH₃, C6-CH₃), 28.3 (CH₃, C6-CH₃), 11.9 (CH₃, C3-CH₃). HRMS (ESI) *m/z*: calcd for C₂₀H₂₁DO₂Na $[M + Na]^+$ 318.1575, found 318.1575.

Cyclopenta[b]furan **5***w*. Leaving substrate **4***w* (59 mg, 0.2 mmol) in CDCl₃ for 5 weeks at room temperature afforded cyclopenta[*b*]-furan **5***w* as a colorless to pale-yellow solid in 60% yield (35 mg) after flash column chromatography (silica gel, eluting with hexanes/ ethyl acetate). Mp: 103.0–104.0 °C. IR (KBr): 3061, 3026, 2957, 2924, 2193, 1645, 1628, 1395, 1219, 1092 cm^{-1. 1}H NMR (300 MHz, CDCl₃): δ 7.34–7.24 (m, 2H, Ar–H), 7.23–7.17 (m, 3H, Ar–H), 5.89 (bs, 1H, 3a-H), 5.67 (q, *J* = 1.6 Hz, 1H, 3-H), 3.83 (bs, 1H, 1-H), 2.30–2.21 (m, 4H, 5-H, 7-H), 1.65 (bs, 3H, 2-CH₃), 1.11

(s, 3H, 6-CH₃), 1.07 (s, 3H, 6-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 194.4 (C, C-8), 174.4 (C, C-4a), 150.2 (C, C-2), 142.9 (C, Ar), 128.5 (2 × CH, Ar), 127.3 (2 × CH, Ar), 126.4 (CH, Ar), 124.2 (CH, C-3), 115.2 (C, C-8a), 95.0 (CH, C-3a), 60.3 (CH, C-1), 51.6 (CD, t, *J* = 21.5 Hz, C-8b), 51.1 (CH₂, C-7), 37.8 (CH₂, C-5), 33.8 (C, C-6), 28.9 (CH₃, C6-CH₃), 28.2 (CH₃, C6-CH₃), 15.4 (CH₃, C2-CH₃). HRMS (ESI) *m/z*: calcd for C₂₀H₂₂DO₂ [M + H]⁺ 296.1755, found 296.1750.

Deuterium Labeling Experiments: Substitution at Branched Dienal C-2.



Aldehyde S5.²⁰ Dry potassium carbonate (6.5 g, 45 mmol), deuterium oxide (7 mL), and ethyl diethylphosphonoacetate (3.3 g, 15 mmol) were vigorously stirred in a dry flask for 20 h at room temperature under a nitrogen atmosphere. Commercially available α -methylcinnamaldehyde (2.19 g, 15 mmol) was then introduced, and stirring was continued for 24 h. Extraction (Et₂O, 20 mL \times 3) was performed after addition of water (10 mL). This crude ester was directly used to obtain aldehyde S5 as a pale-yellow liquid (20% yield over three steps, 0.52 g) by means of the same reduction/oxidation protocol as for the preparation of S2. IR (film): 3059, 3027, 2996, 2981, 2951, 2821, 2728, 1672, 1599, 1584, 1132 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 9.65 (s, 1H), 7.45–7.23 (m, 6H), 6.96 (s, 1H), 2.10 (d, J = 1.1 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 193.9, 157.7, 140.7, 136.1, 134.3, 129.5, 128.3, 128.1, 13.7, the CD triplet signal overlapped with signals at 128.3 and 128.1 ppm. HRMS (ESI) m/z: calcd for C₁₂H₁₁DONa [M + Na]⁺ 196.0843, found 196.0843.

Substrate 4x. Obtained in 70% yield (207 mg) as an orange solid using the general condensation protocol. Mp: 109.0–110.0 °C. IR (KBr): 3065, 3055, 2951, 2866, 1684, 1645, 1526, 1364, 1144 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.77 (bs, 1H, 1'-H), 7.43–7.34 (m, 4H, Ar–H), 7.34–7.24 (m, 1H, Ar–H), 7.21 (bs, 1H, 3'-H), 6.90 (bs, 1H, 5'-H), 2.53 (bs, 4H, 4-H, 6-H), 2.18 (bs, 3H, 4'-CH₃), 1.09 (s, 6H, 5-CH₃, 5-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 198.8 (C, C-1*), 197.8 (C, C-3*), 159.2 (CH, C-3'), 151.4 (CH, C-1'), 141.0 (CH, C-5'), 136.5 (C, Ar), 136.4 (C, C-4'), 129.6 (2 × CH, Ar), 128.3 (2 × CH, Ar), 128.1 (CH, Ar), 128.0 (C, C-2), 125.3 (CD, t, *J* = 24.6 Hz, C-2'), 53.9 (CH₂, C-4**), 52.2 (CH₂, C-6**), 30.0 (C, C-5), 28.4 (2 × CH₃, C5-CH₃), C5-CH₃), 13.9 (CH₃, C4'-CH₃). HRMS (ESI) *m*/*z*: calcd for C₂₀H₂₁DO₂Na [M + Na]⁺ 318.1575, found 318.1568.

Cyclopenta[b]furan **6x**. Obtained as a colorless liquid in 62% yield (92 mg) using the general cycloisomerization protocol (1 equiv of FeCl₃). IR (film): 3056, 2958, 2927, 2870, 1653, 1635, 1398, 1236 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.40–7.31 (m, 2H, Ar–H), 7.31–7.20 (m, 3H, Ar–H), 5.74–5.69 (m, 1H, 2-H), 3.65 (bs, 1H, 8b-H), 2.51 (bs, 1H, 1-H_α), 2.41 (d, *J* = 1.4 Hz, 2H, 5-H), 2.29–2.16 (m, 2H, 7-H), 1.61–1.57 (m, 3H, 3-CH₃), 1.12 (s, 6H, 6-CH₃, 6-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 194.7 (C, C-8), 173.8 (C, C-4a), 141.7 (C, Ar), 139.4 (C, C-3), 129.7 (CH, C-2), 128.4 (2 × CH, Ar), 127.3 (CH, Ar), 124.3 (2 × CH, Ar), 115.8 (C, C-8a), 107.7 (C, C-3a), 51.1 (CH₂, C-7), 50.3 (CH, C-8b), 37.8 (CH₂, C-5), 34.0 (C, C-6), 28.8 (CH₃, C6-CH₃), 28.4 (CH₃, C6-CH₃), 11.9 (CH₃, C3-CH₃), the CD signal was unclear in regard to multiplicity and was found as expected between the signals at 37.8 and 34.0 ppm.

HRMS (ESI) m/z: calcd for $C_{20}H_{21}DO_2Na \ [M + Na]^+$ 318.1575, found 318.1575.

Cyclopenta[b]furan 5x. Leaving substrate 4x (59 mg, 0.2 mmol) in CDCl₃ for 5 weeks at room temperature afforded compound 5x as a pale-yellow solid in 67% yield (40 mg) after flash column chromatography (silica gel, eluting with hexanes/ethyl acetate). Mp: 89.0-90.0 °C. IR (KBr): 3061, 2957, 2924, 2203, 1645, 1630, 1394, 1238, 1140 cm⁻¹. ¹H NMR (300 MHz, CDCl₂): δ 7.35–7.26 (m, 2H, Ar-H), 7.25-7.16 (m, 3H, Ar-H), 5.66 (quint, J = 1.5 Hz, 1H, 3-H), 3.83 (s, 1H, 1-H), 3.57 (s, 1H, 8b-H), 2.32-2.20 (m, 4H, 5-H, 7-H), 1.65 (bs, 3H, 2-CH₃), 1.11 (s, 3H, 6-CH₃), 1.08 (s, 3H, 6-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 194.4 (C, C-8), 174.4 (C, C-4a), 150.3 (C, C-2), 143.0 (C, Ar), 128.5 (2 \times CH, Ar), 127.3 (2 \times CH, Ar), 126.4 (CH, Ar), 124.2 (CH, C-3), 115.3 (C, C-8a), 60.4 (CH, C-1), 51.9 (CH, C-8b), 51.1 (CH₂, C-7), 37.9 (CH₂, C-5), 33.8 (C, C-6), 28.9 (CH₃, C6-CH₃), 28.2 (CH₃, C6-CH₃), 15.4 (CH₃, C2-CH₃), CD signal missing. HRMS (ESI) m/z: calcd for $C_{20}H_{22}DO_2 [M + H]^+$ 296.1755, found 296.1761.

Deuterium Labeling Experiments: Substitution at Branched Dienal C-5.



Aldehyde **S6**. Obtained as a pale-yellow liquid in 22% yield over three steps (255 mg) from α -methylcinnamaldehyde-3- d^{21} (6.7 mmol, 986 mg) using the same tandem Horner–Wadsworth–Emmons protocol/reduction/oxidation protocol for the preparation of **S2** without isolation of the ester intermediate. IR (film): 3053, 2916, 2812, 2731, 1666, 1607, 1304, 1130 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 9.65 (d, J = 7.7 Hz, 1H), 7.45–7.25 (overlapping signals, m, SH; d, J = 15.5 Hz, 1H), 6.27 (dd, J = 15.5 Hz, J = 7.8 Hz, 1H), 2.09 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 193.8 (CH), 157.7 (CH), 140.2 (CD, t, J = 23.4 Hz), 136.0 (C), 134.1 (C), 129.4 (2 × CH), 128.3 (2 × CH), 128.11 (CH), 128.07 (CH), 13.7 (CH₃). HRMS (ESI) m/z: calcd for C₁₂H₁₂DO [M + H]⁺ 174.1024, found 174.1018.

Substrate **4***y*. Obtained in 70% yield (207 mg) as a yellow to orange solid using the general condensation protocol. Mp: 108.0–109.0 °C. IR (KBr): 2952, 2945, 2925, 2866, 1688, 1646, 1568, 1531, 1366, 1174, 1146 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.94 (dd, *J* = 14.8 Hz, *J* = 12.1 Hz, 1H, 2'-H), 7.77 (d, *J* = 12.1 Hz, 1H, 1'-H), 7.42–7.25 (m, 5H, Ar–H), 7.21 (d, *J* = 14.9 Hz, 1H, 3'-H), 2.53 (bs, 4H, 4-H, 6-H), 2.18 (s, 3H, 4'-CH₃), 1.08 (s, 6H, 5-CH₃, 5-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 198.8 (C, C-1*), 197.7 (C, C-3*), 159.3 (CH, C-3'), 151.5 (CH, C-1'), 140.6 (CD, t, *J* = 23.3 Hz, C-5'), 136.3 (C, Ar), 136.2 (C, C-4'), 129.6 (2 × CH, Ar), 128.3 (2 × CH, Ar), 128.05 (CH, Ar), 127.98 (C, C-2), 125.5 (CH, C-2'), 53.9 (CH₂, C-4**), 52.2 (CH₂, C-6**), 29.9 (C, C-5), 28.4 (2 × CH₃, C5-CH₃), C5-CH₃), 13.9 (CH₃, C4'-CH₃). HRMS (ESI) *m/z*: calcd for C₂₀H₂₁DO₂Na [M + Na]⁺ 318.1575, found 318.1576.

Cyclopenta[b]furans **6***l* and **6***y*. An inseparable mixture of compounds **6l** and **6***y* (**6l**:**6***y* = 1:0.15) was obtained as a colorless liquid in 65% yield (96 mg) using the general cycloisomerization protocol (1 equiv of FeCl₃). IR (film): 3059, 3028, 2958, 2927, 1633, 1399, 1236 cm⁻¹. ¹H NMR (300 MHz, CDCl₃, described integration: major component **6l** 1H = 1H, minor component **6***y* 1H = 0.15H): δ 7.39–7.32 (overlapping m, 2H, 0.3H), 7.30–7.21 (overlapping m, 3H, 0.45H), 5.73–5.70 (overlapping m, 1H, 0.15H), 3.66 (overlapping dq, *J* = 7.7 Hz, *J* = 1.7 Hz, 1H, 0.15H), 2.86 (overlapping ddquint, *J* = 17.3 Hz,

J = 7.7 Hz, *J* = 2.4 Hz, 1H, 0.15H), 2.53 (dh, *J* = 17.3 Hz, *J* = 2.0 Hz, 1H), 2.40 (overlapping d, *J* = 1.6 Hz, 2H, 0.3H), 2.23 (overlapping dAB, *J* = 16.1 Hz, 1H, 0.15H), 2.22 (overlapping dAB, *J* = 16.1 Hz, 1H, 0.15H), 1.61−1.57 (overlapping signals, 3H, 0.45H), 1.12 (overlapping s, 6H, 0.9H). ¹³C NMR (75 MHz, CDCl₃): δ 194.6 (C, C), 173.8 (C, C), 141.6 (C, C), 139.4 (C), 139.3 (C), 129.8 (CH), 129.7 (CH), 128.4 (2 × CH, 2 × CH), 127.3 (CH, CH), 124.3 (2 × CH, 2 × CH), 115.7 (C, C), 107.6 (C, C), 51.0 (CH₂, CH₂), 50.4 (CH), 50.3 (CH), 37.8 (CH₂, CH₂), 36.8 (CH₂), 33.9 (C, C), 28.7 (CH₃, CH₃), 28.3 (CH₃, CH₃), 11.9 (CH₃, CH₃), CD signal was missing but could be found when the reaction was run using CH₂Cl₂ saturated with D₂O (**61:6s** = 1:1.5). HRMS (ESI) *m*/*z*: calcd for C₂₀H₂₂DO₂ [M + H]⁺ 296.1755, found 296.1739.

Cyclopenta[b]furan 5y. Leaving compound 4y (59 mg, 0.2 mmol) in CDCl₃ for 5 weeks at room temperature afforded compound 5y as a pale-yellow solid in 65% yield (38 mg) after flash column chromatography (silica gel, eluting with hexanes/ethyl acetate). Mp: 94.5-95.5 °C. IR (KBr): 3062, 2958, 2925, 1646, 1630, 1396, 1213 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.36–7.24 (m, 2H, Ar–H), 7.24– 7.16 (m, 3H, Ar-H), 5.89 (bd, J = 8.3 Hz, 1H, 3a-H), 5.67 (bs, 1H, 3-H), 3.57 (bd, I = 8.4 Hz, 1H, 8b-H), 2.36-2.14 (m, 4H, 5-H, 7-H), 1.65 (bs, 3H, 2-CH₃), 1.11 (s, 3H, 6-CH₃), 1.07 (s, 3H, 6-CH₃). ¹³C NMR (75 MHz, CDCl₃): δ 194.4 (C, C-8), 174.4 (C, C-4a), 150.2 (C, C-2), 142.9 (C, Ar), 128.5 $(2 \times CH, Ar)$, 127.2 $(2 \times CH, Ar)$, 126.4 (CH, Ar), 124.3 (CH, 3-H), 115.2 (C, C-8a), 95.1 (CH, C-3a), 60.0 (CD, t, J = 20.1 Hz, C-1), 51.9 (CH, C-8b), 51.1 (CH₂, C-7), 37.8 (CH₂, C-5), 33.8 (C, C-6), 28.9 (CH₃, C6-CH₃), 28.2 (CH₃, C6-CH₃), 15.4 (CH₃, C2-CH₃). HRMS (ESI) *m/z*: calcd for C₂₀H₂₂DO₂ [M + H]⁺ 296.1755, found 296.1746.

Rearrangement of Cyclopenta[*b*]**furans.** *Cyclopenta*[*b*]*furan* **6b**. Obtained as a colorless solid in 65% yield (71 mg) using the general cycloisomerization protocol with cyclopenta[*b*]furan **5b** (0.5 mmol) as the substrate and FeCl₃ (2 equiv). Mp: 50.5–51.0 °C. IR (KBr): 2962, 2927, 1647, 1626, 1402, 1243, 1135, 1029 cm^{-1.} ¹H NMR (300 MHz, CDCl₃): δ 5.94 (dt, *J* = 5.5 Hz, *J* = 2.4 Hz, 1H), 5.68 (dt, *J* = 5.7 Hz, *J* = 2.3 Hz, 1H), 3.35 (dq, *J* = 7.7 Hz, *J* = 1.8 Hz, 1H), 2.78 (ddt, *J* = 17.8 Hz, *J* = 7.7 Hz, *J* = 2.2 Hz, 1H), 2.48 (dq, *J* = 17.8 Hz, *J* = 2.2 Hz, 1H), 2.24 (d, *J* = 1.2 Hz, 2H), 2.20 (bs, 2H), 1.56 (s, 3H), 1.09 (s, 3H), 1.06 (s, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 194.8 (C), 174.0 (C), 135.0 (CH), 131.8 (CH), 115.7 (C), 104.9 (C), 50.9 (CH₂), 46.4 (CH), 38.2 (CH₂), 37.9 (CH₂), 33.8 (C), 28.52 (CH₃), 28.47 (CH₃), 24.5 (CH₃). HRMS (ESI) *m/z*: calcd for C₁₄H₁₈O₂Na [M + Na]⁺ 241.1199, found 241.1199. *Cyclopenta*[*b*]*furan* **6e**.



Obtained as a colorless liquid in 65% yield (75 mg) using the general cycloisomerization protocol with cyclopenta[*b*]furan **5e** (0.5 mmol) as the substrate and FeCl₃ (2 equiv). IR (film): 2961, 2928, 1651, 1630, 1402, 1232 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 5.99 (dt, *J* = 5.7 Hz, *J* = 2.3 Hz, 1H, 2-H), 5.67 (dt, *J* = 5.7 Hz, *J* = 2.1 Hz, 1H, 3-H), 3.43 (dm, *J* = 7.6 Hz, 1H, 8b-H), 2.72 (ddt, *J* = 17.7 Hz, *J* = 7.7 Hz, *J* = 2.1 Hz, 1H, 1-H_{*a*}), 2.48 (dq, *J* = 17.8 Hz, *J* = 2.1 Hz, 1H, 1-H_{*a*}), 2.25 (bs, 2H, 5-H), 2.20 (bs, 2H, 7-H), 1.96–1.74 (m, 2H, 1'-H), 1.08 (s, 3H, 6-CH₃), 1.07 (s, 3H, 6-CH₃), 0.91 (t, *J* = 7.4 Hz, 3H, 2'-H). ¹³C NMR (75 MHz, CDCl₃): δ 194.7 (C, C-8), 174.3 (C, C-4a), 135.7 (CH, C-2), 130.6 (CH, C-3b), 38.3 (CH₂, C-1), 37.8 (CH₂, C-5), 33.9 (C, C-6), 30.2 (CH₂, C-1'), 28.7 (CH₃, C6-CH₃), 28.3 (CH₃, C6-CH₃), 7.7 (CH₃, C-2'). HRMS (ESI) *m*/*z*: calcd for C₁₅H₂₀O₂Na [M + Na]⁺ 255.1355, found 255.1353.

ASSOCIATED CONTENT

Supporting Information

Copies of ¹H and ¹³C NMR spectra for all new compounds and 2D spectra for key structures. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: mischne@iquir-conicet.gov.ar.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Universidad Nacional de Rosario and Fundación Josefina Prats for financial support. M.J.R. thanks CONICET for fellowships. We gratefully acknowledge Dr. Guillermo R. Labadie and Dr. Carina M. J. Delpiccolo for HRMS measurements.

REFERENCES

For reviews, see: (a) Trost, B. M. Acc. Chem. Res. 1990, 23, 34.
 (b) Malacria, M. Chem. Rev. 1996, 96, 289. (c) Fürstner, A.; Davies, P. W. Angew. Chem., Int. Ed. 2007, 46, 3410. (d) Jiménez-Núñez, E.; Echavarren, A. M. Chem. Rev. 2008, 108, 3326. (e) Soriano, E.; Marco-Contelles, J. Acc. Chem. Res. 2009, 42, 1026. (f) Yamamoto, Y. Chem. Rev. 2012, 112, 4736. (g) Watson, I. D. G.; Toste, F. D. Chem. Sci. 2012, 3, 2899.

(2) For reviews of the Nazarov reaction, see: (a) Habermas, K. L.; Denmark, S. E.; Jones, T. K. Org. React. 1994, 45, 1. (b) Tius, M. A. Eur. J. Org. Chem. 2005, 2193. (c) Pellissier, H. Tetrahedron 2005, 61, 6479. (d) Frontier, A. J.; Collison, C. Tetrahedron 2005, 61, 7577. (e) Shimada, N.; Stewart, C.; Tius, M. A. Tetrahedron 2011, 67, 5851. (f) Spencer, W. T., III; Vaidya, T.; Frontier, A. J. Eur. J. Org. Chem. 2013, 3621. For studies of pentadienyl cation electrocyclizations, see: (g) Deno, N. C.; Pittman, C. U., Jr.; Turner, J. O. J. Am. Chem. Soc. 1965, 87, 2153. (h) Sorensen, T. S. J. Am. Chem. Soc. 1965, 87, 5075. (i) Deno, N. C.; Scholl, P. C. J. Am. Chem. Soc. 1971, 93, 2702. (j) Davis, R. L.; Tantillo, D. J. Curr. Org. Chem. 2010, 14, 1561. For a review of contemporary carbocation chemistry, see: (k) Naredla, R. R.; Klumpp, D. A. Chem. Rev. 2013, 113, 6905.

(3) (a) Elia, G. R.; Childs, R. F.; Shaw, G. S. Can. J. Chem. 1992, 70, 2065.
(b) Miller, A. K.; Trauner, D. Angew. Chem., Int. Ed. 2003, 42, 549.
(c) Miller, A. K.; Byun, D. H.; Beaudry, C. M.; Trauner, D. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 12019.

(4) For examples, see: (a) Denmark, S. E.; Hite, G. A. Helv. Chim. Acta 1988, 71, 195. (b) Yoshimatsu, M.; Matsuura, Y.; Gotoh, K. Chem. Pharm. Bull. 2003, 51, 1405. (c) Miller, A. K.; Banghart, M. R.; Beaudry, C. M.; Suh, J. M.; Trauner, D. Tetrahedron 2003, 59, 8919. (d) Lin, C.-C.; Teng, T.-M.; Odedra, A.; Liu, R. S. J. Am. Chem. Soc. 2007, 129, 3798. (e) Jung, M. E.; Yoo, D. J. Org. Chem. 2007, 72, 8565. (f) Marcus, A. P.; Lee, A. S.; Davis, R. L.; Tantillo, D. J.; Sarpong, R. Angew. Chem., Int. Ed. 2008, 47, 6379.

(5) (a) Riveira, M. J.; Gayathri, C.; Navarro-Vázquez, A.; Tsarevsky,
N. V.; Gil, R. R.; Mischne, M. P. Org. Biomol. Chem. 2011, 9, 3170.
(b) Riveira, M. J.; Mischne, M. P. Chem.—Eur. J. 2012, 18, 2382.

(6) For publications on natural and synthetic cyclopenta[b]furans of interest, see: (a) Larock, R. C.; Lee, N. H. J. Org. Chem. 1991, 56, 6253. (b) Che, Y.; Araujo, A. R.; Gloer, J. B.; Scott, J. A.; Malloch, D. J. Nat. Prod. 2005, 68, 435. (c) Li, N.; Di, L.; Gao, W.-C.; Wang, K.-J.; Zu, L.-B. J. Nat. Prod. 2012, 75, 1723. (d) Reddy, N. K.; Vijaykumar, B. V. D.; Chandrasekhar, S. Org. Lett. 2012, 14, 299. (e) Ribeiro, N.; Thuaud, F.; Nebigil, C.; Désaubry, L. Bioorg. Med. Chem. 2012, 20, 1857 and references therein.

(7) (a) Silva López, C.; Nieto Faza, O.; Álvarez, R.; de Lera, A. R. J. Org. Chem. 2006, 71, 4497. (b) Nieto Faza, O.; Silva López, C.; Álvarez, R.; de Lera, A. R. Chem.—Eur. J. 2009, 15, 1944.

(8) (a) Grant, T. N.; Rieder, C. J.; West, F. G. *Chem. Commun.* **2009**, 5676. (b) Kwon, Y.; McDonald, R.; West, F. G. *Angew. Chem., Int. Ed.* **2013**, 52, 8616.

(9) de Lera and co-workers⁷ addressed the isomerization of the triene moiety of conjugated esters to give bicyclo[3.1.0]hexenes through computational analysis. The evidence suggests that it would proceed through a pentadienyl cation electrocyclic ring closure followed by a barrierless olefinic trapping of the cyclopentenyl cation intermediate.

(10) Valenta, P.; Drucker, N. A.; Bode, J. W.; Walsh, P. J. Org. Lett. **2009**, *11*, 2117.

(11) Chandrasekhar, S.; Venkat Reddy, M.; Srinivasa Reddy, K.; Ramarao, C. Tetrahedron Lett. 2000, 41, 2667.

(12) Riveira, M. J.; Tekwani, B. L.; Labadie, G. R.; Mischne, M. P. *Med. Chem. Commun.* **2012**, *3*, 1294.

(13) Bharathi, P.; Periasamy, M. Org. Lett. 1999, 1, 857.

(14) Patel, B. A.; Kim, J.-I. I.; Bender, D. D.; Kao, L.-C.; Heck, R. F. J. Org. Chem. 1981, 46, 1061.

(15) Mahata, P. K.; Barun, O.; Ila, H.; Junjappa, H. Synlett 2000, 1345.

(16) Shao, L.-X.; Li, J.; Wang, B.-Y.; Shi, M. Eur. J. Org. Chem. 2010, 6448.

(17) Pommer, H. Justus Liebigs Ann. Chem. 1953, 579, 47.

(18) Larpent, C.; Meignan, G.; Patin, H. Tetrahedron 1990, 46, 6381.

(19) Cao, X.-P. Tetrahedron 2002, 58, 1301.

(20) Seguineau, P.; Villieras, J. Tetrahedron Lett. 1988, 29, 477.

(21) Jobashi, T.; Kawai, A.; Kawai, S.; Maeyama, K.; Oike, H.; Yoshida, Y.; Yonezawa, N. *Tetrahedron* **2006**, *62*, 5717.